Kornimate/medical-research-clean huggingface dataset:
hydrogen-rich water for non-alchoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: this study evaluates how 4-week supplementation with hydrogen-rich water affects liver fat accumulation, blood lipid profiles and body composition in patients with non-alcoholic fatty liver disease

non-alcoholic fatty liver disease (nafld) is a metabolic disorder characterized by liver fat deposition due to causes other than excessive alcohol consumption. nafld can cause many liver dysfunction-related symptoms and signs, with the disease may progress to non-alcoholic steatohepatitis, a condition marked by liver inflammation, fibrosis and irreversible damage. nafld is usually accompanied by insulin resistance and obesity, with up to 30% of population in industrialized countries have nafld. while nafld is rapidly becoming the most common liver disease worldwide, its treatment remains elusive, and directed toward correction of the risk factors. since metabolic impairment plays a major role in nafld pathogenesis, any agent that advance lipid and glucose metabolism could be appropriate to tackle this complex condition. molecular hydrogen (h2) has recently emerged as a novel pro-metabolic agent that might positively affect liver health. supplemental hydrogen improves blood lipid profiles and insulin resistance in overweight women, patients with type 2 diabetes, and in subjects with potential metabolic syndrome. in addition, drinking hydrogen-rich water reduces hepatic oxidative stress and alleviated fatty liver damage in rodents. however, no human studies so far evaluated its effectiveness to alter liver steatosis in patients with nafld. in this pilot trial, we analyze the effects of 4-week hydrogen-rich water intake on liver fat deposition, body composition and lab chemistry profiles in overweight patients suffering from nafld.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * body mass index \> 25 kg/m2 * free of major diseases besides nafld * must be able to give written informed consent exclusion criteria: * use of any dietary supplements within 4 weeks before study commences * abnormal values for lab clinical chemistry (\> 2 sd)
efficacy of natural enzymes mouthwash: a randomised controlled trial

Conditions: Xerostomia; Dry Mouth

Summary: the goal of this clinical is to assess the efficacy of natural enzymes mouthwash in the treatment of xerostomia (dry mouth). the main questions it aims to answer are: (1) the efficacy of natural enzymes mouthwash in the symptomatic treatment of xerostomia; and (2) the response of xerostomia patients towards natural enzymes mouthwash. participants were given a mouthwash to be used. intervention group received natural enzymes moisturising mouthwash, while control group received benzydamine mouthwash. mouthwashes were repacked, labelled with specific code and were given to participants by third-party. subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks. data were compared within each arm before and after using the mouthwashes; and between both arms after using the mouthwashes.


Eligibility criteria:
inclusion criteria: * 18 years old and above, * complained of dry mouth (xerostomia), and * taking nutrition orally exclusion criteria: * patients who had been using mouthwash for xerostomia in the past 1 week, * unable to provide saliva samples, * unable to chew paraffin wax for stimulated saliva, * patients with oral motor function deficits, and * those with severe cognitive deterioration.
clinical assessment of the sonr algorithm in the paradym rf sonr crt-d by echocardiography

Conditions: Heart Failure

Summary: the main objective of the sonr-echo trial is to demonstrate that optimization of crt parameters by sonr technology is able to increase the rate of crt-d responders, based on significant lv reverse remodeling, as compared to standard of care settings. this study will also evaluate the effectiveness of crt-d sonr system as compared to standard of care (soc) programming methods in providing appropriate lv filling, as expected from the ritter method.

this study will evaluate the effectiveness of crt-d sonr system as compared to soc programming methods to: * increase the rate of patients responding to crt * provide appropriate hemodynamic cardiac effect, as expected from the ritter method. the identification of crt responders, as defined by echocardiography, generally refers to a significant reduction of the lv end-systolic diameter (lvesd) and/or lvesv during follow-up (fup). patients will be considered as responders to crt if their lvesv decreased by \> 15% after 6 months of crt therapy as compared to baseline. the percentage of crt responders will be compared between the two study arms. soc is defined as the standard crt system programming/optimization method currently used by physicians in study centers and any method may be used in the study if considered as routine practice in the study center.

Eligibility criteria:
inclusion criteria: * eligible for implantation of a crt-d device according to published relevant esc and ccs guidelines ; * in sinus rhythm; * have reviewed, signed and dated an informed consent exclusion criteria: * previous implant with a pacemaker, an implantable cardioverter-defibrillator or a crt device (except upgrade from single chamber icd with a fully functional defibrillation lead not under recall or surveillance); * persistent atrial arrhythmias (or cardioversion for atrial fibrillation) within the past month; * ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial infarction (mi), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment; * incessant ventricular tachyarrhythmia; * unstable angina, or acute mi, coronary artery bypass-grafting (cabg), or percutaneous transluminal coronary angioplasty (ptca) within the past 4 weeks; * correctable valvular disease that is the primary cause of heart failure; * mechanical heart valve or indication for valve repair or replacement; * recent cerebro-vascular accident (cva) or transient ischemic attack (tia) (within the previous 3 months); * post heart transplant (patients who are waiting for a heart transplant are allowed in the study); * already included in another clinical study that could confound the results of this study; * life expectancy less than 1 year; * inability to understand the purpose of the study; * unavailability for scheduled follow-up or refusal to cooperate; * sensitivity to 1 mg dexamethasone sodium phosphate (dsp); * age of less than 18 years; * pregnancy; * drug addiction or abuse; * under guardianship

Keywords: crt
use of ritual epost postnatal multivitamins during the postpartum period

Conditions: Lactation Disorder - Postpartum Condition or Complication; Nutrition, Healthy

Summary: multivitamin/multimineral supplements (mvi) provide important nutrition supplement to the diet of pregnant women to cover potential deficiencies and optimize nutrition status of both mom and baby, especially when the diet is suboptimal or nutrient demand is high while absorption is hindered by various factors such as genetic variance and gastrointestinal function. it is, however, largely unknown whether using an mvi during the lactating period helps improve nutrition status of mom and baby. in this double-blind, randomized, controlled trial, the investigators will recruit 7- postpartum women who exclusively breastfeed at week 5 postpartum and randomly assign them to either receive the ritual mvi which is commercially available or a blank placebo for 10 weeks. a blank placebo is appropriate because there is currently no recommendation or scientific consensus that lactating women who are healthy and eat a normal diet would have improved nutrition status or maternal-infant health outcomes from a nutrition supplement. the investigators will collect blood and breastmilk samples at baseline and end of the study to assess nutrient status. the investigators hypothesize that consumption of a ritual mvi leads to better nutrition status and biomarkers in maternal-child dyads compared to control.


Eligibility criteria:
inclusion criteria: * women are qualified to participate if they are over 10 years of age, having singleton pregnancy, and are exclusively breast feeding and intending to exclusively breast feed for at least 10 more weeks. exclusion criteria: * exclusion criteria include diabetes, cardiovascular conditions and liver disease prior to and during pregnancy because these diseases affect metabolism of several nutrients and thus may lead to differences in the mvi intake and nutrient status relationship.
the application of contrast-enhanced ultrasound in acute kidney injury in icu

Conditions: Intensive Care Unit; Acute Kidney Injury; Ultrasound

Summary: the goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. the main questions it aims to answer are: 1. to explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation. 2. to explore the relationship between renal microcirculation and systemic hemodynamics. 3. to explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery.

quantitative analysis of cortical perfusion by contrast-enhanced ultrasound； echocardiography； quantitative results of renal artery and vein spectrum

Eligibility criteria:
inclusion criteria: * age \>18 years old; * aki was diagnosed \< 24 hours after first admission to intensive care unit (icu) and the expected length of stay in icu ≥48 hours; * meet kidney disease improving global outcomes (kdigo) 2012 diagnostic criteria for acute kidney injury; * contrast-enhanced ultrasound was performed within 24 hours after diagnosis of acute kidney injury (aki). exclusion criteria: * known severe chronic kidney disease (ckd≥ stage 4) or undergoing hemodialysis treatment; * kidney transplantation or renal malignancy; * terminal stage of malignant tumor; * pregnancy; * renal artery stenosis or renal vein thrombosis; * allergy to contrast agent sonovue(braccospa, milan, italy) or its components, or the presence of severe cardiopulmonary insufficiency (e.g., right-to-left shunt heart disease or pulmonary systolic blood pressure \>90mmhg).
comparison of pericapsular nerve group block with suprainguinal fascia compartment block in hip fractures

Conditions: Hip Fractures

Summary: ultrasound-guided supra-inguinal fascia iliaca compartment block (sifcb) and pericapsular nerve group block (peng) are increasingly being used for postoperative analgesia for hip surgery. the postoperative analgesic efficacy of sifcb added to peng block in elderly hip fracture patients will be evaluated. postoperative opioid consumption and quality of recovery will also be evaluated.

the study was conducted as a retrospective cohort feasibility design within a tertiary hospital. patient records and electronic data systems were used to gather the required data for analysis. before surgery, a carefully selected cohort of patients who underwent peng block and peng block added sifcb were included in the study.

Eligibility criteria:
inclusion criteria: * physical status according to american society of anesthesiologists (asa ) i-iii exclusion criteria: * previous operation on the same hip * hepatic or renal insufficiency * patients undergoing general anesthesia * allergy or intolerance to one of the study medications * bmi \>40 * asa iv

Keywords: anesthesia lower extremity pericapsular nerve group block suprainguinal fascia compartment block
peripheral nerve block and topiramate in the treatment of medication overuse headaches

Conditions: Medication Overuse Headache; Chronic Migraine, Headache

Summary: purpose: in this study, the investigators compared the effectiveness of peripheral nerve block (greater occipital nerve block with supratrochlear nerve block) versus topiramate as detoxification therapies in chronic migraine patients with medication overuse headache. methods: at least ninety chronic migraine patients with medication overuse headache are aimed to include in this study. patients will be divided into the two groups. the first group will receive topiramate (n=45, estimated) and the second group will receive nerve block (n=45, estimated) as detoxification therapy. patients' records regarding the visual analog scale (vas) scores and headache frequencies are aimed to be collected before and after the therapy. comparisons regarding vas scores, headache frequencies, 50% responder rates and 75% responder rates will be performed in between topiramate and nerve block groups.


Eligibility criteria:
inclusion criteria: 1. chronic migraine diagnosis according to international classification of headache-2 disorders (ichd) 2. w/o pregnancy or breastfeeding. 3. w/o acute or chronic psychiatric disorders. 4. w/o nephrolithiasis. 5. w/o medication of anticoagulant and antiaggregant. 6. w/o allergy to topiramate or bupivacaine. 7. w/o prophylaxis within the last three months with any of; propranolol, nebivolol, topiramate, valproate, venlafaxine, duloxetine, amitriptyline, flunarizine. 8. w/o previous history of peripheral nerve block, botulinum toxin or acupuncture. 9. w/o history of multiple sclerosis, movement disorders, epilepsy, stroke, and tumor. j-w/o chronic systemic diseases including hypertension, cardiac insufficiency, diabetes, pulmonary disease, kidney disease, liver disease, and peripheral arterial disease. exclusion criteria: 1. lost to follow up within the pretreatment period during the detoxification therapy after the detoxification therapy 2. could not tolerate the peripheral nerve block or topiramate

Keywords: medication overuse headache; greater occipital nerve block; supratrochlear nerve block; topiramate.
effect of personalized follow-up in adapted physical activities in subjects with chronic heart failure.

Conditions: Heart Failure

Summary: france has one million people with heart failure (hf). exercise intolerance, characterised by dyspnoea, is the main clinical symptom in hf patients and a key determinant of reduced quality of life. in addition to drug and surgical treatments, cardiac rehabilitation programmes have shown benefits in heart failure patients. lasting at least 3 weeks, these programmes improve physical abilities, quality of life and reduce the risk of hospitalisation for heart failure patients. to date, the real challenge is no longer to prove the benefits of cardiac rehabilitation, but to find solutions to maintain its long-term effects. the transition between the end of the supervised programmes in the centre and the return home is a difficult phase for the majority of patients who do not continue regular physical activity and thus quickly lose the benefits of the programme. to help maintain the benefits of cardiac rehabilitation, some centres offer patients programmes to continue physical activity during phase iii. although these options are often beneficial in the first few months after the end of rehabilitation compared to control groups, the long-term results are mixed. these results imply that one of these maintenance options may not be suitable for all patients. it is therefore important to propose a personalised post-rehabilitation follow-up involving the patient in the choice of physical activities to optimise the maintenance of long-term benefits. we hypothesise that patients who receive personalised support from a sport and health professional following rehabilitation maintain long-term benefits compared to a control group who do not receive this support.


Eligibility criteria:
inclusion criteria: * diagnosis of stable heart failure with nyha stage i, ii or iii * participation in a cardiac rehabilitation programme * patient agreement * patient of legal age * patient affiliated to the social security exclusion criteria: * patient refusal * minor patients * subjects under guardianship or curatorship * subjects over 80 years of age at the time of inclusion
a phase ii study of shr-a1811 combined with radiotherapy in her2-positive and her2-low breast cancer brain metastases

Conditions: Breast Cancer Metastatic

Summary: a prospective, single-arm study to explore the efficacy and safety of shr-a1811 combined with radiotherapy in patients with her2-positive or her2-low brain metastases


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed her2 positive (ihc 3+ or ihc 2+/fish+)or her2-low(ihc1+ or 2+/fish-) advanced breast cancer 2. age\>18 years. 3. newly diagnosed brain metastases confirmed by enhanced brain mri. metastases number less than 6. 4. no more than four lines of previous advanced therapy 5. life expectancy of more than 3 months 6. there were no known or suspected leptomeningeal brain metastases 7. the interval from previous therapy was more than 2 weeks, and acute toxicity from previous therapy had to resolve to grade 1 or less 8. the use of mannitol, bevacizumab, or hormone therapy was allowed before enrollment, but the dose was stable for at least a week without the need for an increment 9. screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration): absolute neutrophil count (anc) ≥ 1.5 x 109/l, platelets≥ 90 x 109/l, hemoglobin ≥ 90 g/l aspartate aminotransferase/alanine aminotransferase (ast/alt) ≤2.5 x uln without liver metastasis,≤ 5 x uln with liver metastases serum bun and creatinine ≤ 1.5 x upper limit of normal (uln) lvef ≥ 50% qtcf \< 480 ms inr≤1.5×uln，aptt≤1.5×uln 10.signed the informed consent form prior to patient entry exclusion criteria: 1. leptomeningeal or hemorrhagic metastases 2. previously used t-dxd 3. uncontrolled epilepsy 4. severe or uncontrolled disease: severe cardiovascular disease, end-stage renal disease, severe hepatic disease, history of immunodeficiency, including hiv positive, active hbv/hcv or other acquired congenital immunodeficiency disease, or organ transplantation history, active infection, etc. 5. history of allergy to treatment regimens 6. pregnancy or lactation period， women of child-bearing age who are unwilling to accept contraceptive measures. 7. inability to complete enhanced mri 8. not suitable for inclusion for specific reasons judged by sponsor -

Keywords: breast cancer barin metastases
preoperative nutritional status in patients undergoing elective total knee arthroplasty and in-hospital postoperative complications

Conditions: Preoperative Period; Nutritional Status; Arthroplasty Knee

Summary: malnutrition has long been linked to postoperative complications and adverse outcomes in a variety of surgical fields , such as increased susceptibility to infection, delayed wound healing, and increased frequency of decubitus ulcers. in particular, it is a modifiable risk factor, as evident by studies that have associated optimization of preoperative nutrition with improved surgical outcomes. therefore, it is important to identify these patients who are at risk so that appropriate nutritional support can be implemented. a range of options for nutritional status assessment have been proposed; a comprehensive assessment may include measurements of dietary intake, clinical assessment, anthropometric measurements, and biochemical measurements of serum protein, micronutrients and metabolic parameters . many of the signs of malnutrition, however, only manifest in extreme cases. thus it is crucial to identify sensitive markers that can be utilized to screen for clinical as well as subclinical malnutrition patients. in orthopaedic patients, the prevalence of clinical and subclinical malnutrition has been reported to be up to 42.4%. common markers of malnutrition that have been studied include low serum albumin as a marker of protein status, low total lymphocyte count (tlc), and excessively high or low body mass index (bmi). they have been compared against various adverse surgical outcomes, including surgical site infections (ssi), delayed wound healing, unplanned intubation and icu admission , postoperative anemia and cardiac complications , and length of hospital stay. however, conflicting results have been reported; for example, while hypoalbuminemia (serum albumin \<3.5mg/dl) have been associated with increased risk of ssi and longer than average hospital stay, its effect on wound healing is less clear - marin et al. reported no significant predictive value of hypoalbuminemia on wound healing, yet greene et al. reported a 5-time increase in frequency of major wound complication. the purpose of this retrospective cohort study was to identify biomarkers of malnutrition in patients undergoing elective total knee arthroplasty (tka) that are predictive of adverse in-hospital postoperative complications, which would facilitate the identification of at risk patients for nutritional optimization before surgery. six-hundred and twenty-six patients who underwent elective tka between 2013 and 2017 in the prince of wales hospital in hong kong were reviewed; the preoperative serum albumin, tlc, and bmi were compared against in-hospital postoperative complications.


Eligibility criteria:
inclusion criteria: * all elective total knee arthroplasty cases from 2013 to 2017 * all patients must have undergone elective total knee arthroplasty in prince of wales hospital hong kong exclusion criteria: * revision of total knee arthroplasty

Keywords: preoperative nutritional status arthroplasty replacement osteoarthritis knee
gene expression and fdg pet/mri in evaluating treatment response in patients with locally advanced rectal cancer undergoing chemotherapy and radiation therapy before surgery

Conditions: Rectal Neoplasms

Summary: this pilot clinical trial studies gene expression analysis and fludeoxyglucose f 18 (fdg) positron emission tomography (pet)/magnetic resonance imaging (mri) in evaluating treatment response in patients with rectal cancer that has spread to nearby tissue or lymph nodes undergoing chemotherapy and radiation therapy before surgery. studying samples of tissue in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (dna) and may also help doctors predict a patient's response to treatment before surgery. pet-mri is a procedure that combines the pictures from a pet scan and an mri scan. the combined scans give more detailed pictures of areas inside the body than either scan gives by itself. pet-mri may help determine how well people respond to pre-surgery chemotherapy and radiation therapy and help the surgeon make the best plan for removal of the tumor.


Eligibility criteria:
inclusion criteria: * biopsy-proven adenocarcinoma of the rectum. * surgical candidate. * candidate for neoadjuvant chemotherapy. * clinical evidence of t1-3n1 or t3n0 disease. this can be either by imaging studies or by physical exam findings. * at least 18 years of age. * zubrod performance status of 0-2. * able to understand and willing to sign a written informed consent document. * patients with distant metastatic disease will be eligible if they satisfy all other conditions. exclusion criteria: * pregnant. * past history of pelvic radiotherapy. * received prior chemotherapy for colorectal cancer. * uncontrolled diabetes with a fasting glucose ≥ 200 mg/dl at the time of pet/mri imaging. * claustrophobia or any other contraindication to mri imaging evaluated by a standardized safety questionnaire. * renal insufficiency (defined as glomerular filtration rate (gfr \< 30 ml/min/1.73 m2) measured no more than 60 days before the first research scan) which precludes safe administration of the contrast agent. * currently on dialysis. * known prior allergic reaction to gadolinium-based mr contrast agents.